Is natalizumab a breakthrough in the treatment of multiple sclerosis?

@article{Doggrell2003IsNA,
  title={Is natalizumab a breakthrough in the treatment of multiple sclerosis?},
  author={Sheila Anne Doggrell},
  journal={Expert Opinion on Pharmacotherapy},
  year={2003},
  volume={4},
  pages={1001 - 999}
}
  • S. Doggrell
  • Published 1 June 2003
  • Medicine, Psychology
  • Expert Opinion on Pharmacotherapy
In patients with either relapsing-remitting or secondary-progressive multiple sclerosis, there were fewer new lesions/patient with natalizumab (0.7 and 1.1 with natalizumab 3 and 6 mg/kg every 28 days, respectively) than in the placebo group (9.6 new lesions/patient) over 6 months. There were also fewer relapses in the natalizumab groups than the placebo group. However, there were no changes in the Expanded Disability Status Scale scores in any of the groups. Natalizumab was well-tolerated… 
View on Taylor & Francis
direct-ms.org
5 Citations

5 Citations

Oxidative Stress and Lymphocyte Alterations in Chronic Relapsing Experimental Allergic Encephalomyelitis in the Rat Hippocampus and Protective Effects of an Ethanolamine Phosphate Salt

A protective role of EAP is suggested in the CR-EAE rat hippocampus as a delay in the onset of the clinical signs of the disease as well as a decrease in inflammatory infiltrates and alterations of the antioxidant defences in the hippocampus.

Massenspektrometrisches Fragmentierungsverhalten oxidierter schwefelhaltiger Aminosäuren und ihr Nutzen für die Proteomforschung

Der wachsende Markt an Arzneistoffen auf Proteinbasis fuhrt zu einem wachsenden Bedarf an analytischen Methoden, die zur Aufklarung der Proteinstruktur und auftretenden alterungsbedingten Schaden…

Determinação de Anticorpos Anti-Mielina na Esclerose Múltipla

Thérapie de recrutement anti-leucocytaire pour le traitement de crises épileptiques et de l'épilepsie

To Market, To Market—2004

References

SHOWING 1-10 OF 16 REFERENCES

A controlled trial of natalizumab for relapsing multiple sclerosis.

In a placebo-controlled trial, treatment with natalizumab led to fewer inflammatory brain lesions and fewer relapses over a six-month period in patients with relapsing multiple sclerosis.

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  • G. Ebers
  • Medicine, Psychology
    The Lancet
  • 1998

Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.

Data show that the IMAs have similar effects on several physical and inflammatory measures and Avonex has demonstrated efficacy in slowing cognitive progression in relapsing MS.

Interferons in relapsing remitting multiple sclerosis: a systematic review

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  • Medicine, Psychology
    Lancet
  • 1998
Subcutaneous interferon beta-1a is an effective treatment for relapsing/remitting MS in terms of relapse rate, defined disability, and all MRI outcome measures in a dose-related manner, and it is well tolerated.

The effect of anti-α4 integrin antibody on brain lesion activity in MS

Short-term treatment with monoclonal antibody against α4 integrin results in a significant reduction in the number of new active lesions on MRI, and further studies will be required to determine the longer term effect of this treatment on MRI and clinical outcomes.

A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis.

European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

Glatiramer acetate significantly reduced MRI‐measured disease activity and burden in patients with relapsing remitting multiple sclerosis and increased over time.

Rating neurologic impairment in multiple sclerosis

A new Expanded Disability Status Scale (EDSS) is presented, with each of the former steps (1,2,3 … 9) now divided into two (1.0, 1.5, 2.0 … 9).

A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis